Advances in Advanced TNBC


Continue Reading

Currently, TNBC is predominantly treated with chemotherapy.

Clinical management of patients with TNBC is challenging, and genetic characterization has defined molecular subtypes, each of which responds differently to chemotherapy.11-13 Pathological and molecular characterization is important in the management of patients with TNBC, which harbor several hallmark mutations, including TP53, PI3KCA, PTEN, BRCA1, and BRCA2, and loss of RB1 and BRCA1.  

The subset of BRCA-associated breast cancer, or “BRCAness,” is characterized by a heightened sensitivity to damage from DNA cross-linking, which may explain why platinum salts are effective in these tumors.

Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, may be an effective treatment for BRCA-mutant tumors. PARP inhibitors have been shown to target single-stranded DNA repair with homologous recombination that arise in this setting.

Ongoing clinical trials are evaluating PARP inhibition. These include olaparib in the OlympiAD study (ClinicalTrials.gov Identifier: NCT02000622), niraparib in BRAVO (ClinicalTrials.gov Identifier: NCT01905592), and talazoparib in EMBRACA (ClinicalTrials.gov Identifier: NCT01945775).

The presence of tumor-infiltrating lymphocytes and the overexpression of PD-L1 supports the evaluation of checkpoint inhibitors in TNBC.

KEYNOTE-119 (ClinicalTrials.gov Identifier: NCT02555657) is a phase 3 trial evaluating single-agent pembrolizumab vs single-agent chemotherapy for metastatic TNBC.

The phase 3 KEYNOTE-355 trial (ClinicalTrials.gov Identifier: NCT02819518) will compare pembrolizumab plus chemotherapy vs chemotherapy alone among patients with previously untreated, locally recurrent, inoperable or metastatic TNBC. This study is still accruing patients. Identifying biomarkers of response will be important for identifying patients who are likely to benefit from immunotherapy.

Data with checkpoint inhibitors are, however, not mature and were not available at the ASCO meeting, Dr Mayer indicated.  

Conclusions

Novel drugs and combinations are helping oncologists overcome resistance to endocrine and HER2-targeted therapies. The management of TNBC, while still challenging, has also seen significant advances, and molecular profiling in these tumors will help personalize treatment for patients.

References

  1. Milani A, Guena E, Mittica G, Valabrega G. Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future direction. World J Clin Oncol. 2014;5(5):990-1001.
  2. Chlebowski RT. Strategies to overcome endocrine therapy resistance in hormone receptor-positive breast cancer. Clin Invest. 2014;4(1):19-33.
  3. Luqmani YA, Alam-Eldin N. Overcoming resistance to endocrine therapy in breast cancer: New approaches to a nagging problem. Med Princ Pract. 2016;25(suppl 2):28-40.
  4. Cardoso F, Villanueva C, Royce M, et al. Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study. J Clin Oncol. 2017;35 (suppl; abstr 1010).
  5. Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. J Clin Oncol. 2017;35 (suppl; abstr 1000).
  6. Lindemann GJ, Lok SW, Bergin AR, et al. Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study. J Clin Oncol. 2017;35 (suppl; abstr 1044).
  7. Wang R, Dang C. Current standards and new treatment insights in HER2-driven metastatic breast disease. Am J Hematol Oncol. 2016;12(10):12-17.
  8. Drakaki A, Hurvitz SA. HER2-positive breast cancer: Update on new and merging agents. Am J Hematol Oncol. 2015;11(4):17-23.
  9. Gradishar WJ, Hegg R, Im S-A, et al. Phase II study of lapatinib (L) plus trastuzumab (T) and an aromatase inhibitor (AI) vs T + AI vs L + AI in postmenopausal women (PMW) with HER2+, HR+, metastatic breast cancer (MBC): ALTERNATIVE. J Clin Oncol. 2017;35 (suppl; abstr 1004).
  10. Perez EA, Barrios CH, Eiermann W, et al. Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± oeruzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE. J Clin Oncol. 2017;35 (suppl; abstr 1003).
  11. Colligon J, LOusberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press). 2016;8:93-107.
  12. Anders C, Abramson V, Tan T, Dent R. The evolution of triple-negative breast cancer: From biology to novel therapeutics. Am Soc Clin Oncol Educ Book. 2016;35:34-42.
  13. Jitariu A-A, Cîmpean AM, Ribatti D, Raica M. Triple negative breast cancer: the kiss of death. Oncotarget. 2017. doi: 10.18632/oncotarget.16938. [Epub ahead of print]